A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) In Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate -2 or High-Risk Myelodysplastic Syndrome (MDS)
A study for patients with Myelodysplastic Syndrome (MDS) using study drug Vadastuximab Talirine
Sponsor: Seattle Genetics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAQ6461
U.S. Govt. ID: NCT02706899
Contact: Joseph Jurcic: 646-317-5191 / jgj2110@cumc.columbia.edu
Additional Study Information: This study is for patients have been diagnosed with Intermediate or High-risk myelodysplastic syndrome (MDS). MDS is a condition where there is a low count of white blood cells, red blood cells and platelets because of a malfunction of bone marrow that is responsible for producing healthy mature blood cells. evaluate the combination of the investigational medicine, vadastuximab talirine (SGN-CD33A) and azacitidine in subjects with previously untreated Intermediate or High-risk MDS. In the Phase 1 portion of the trial, multiple dose levels of vadastuximab talirine will be evaluated in combination with azacitidine. One dose will be selected for the randomized, double-blind , placebo-controlled Phase 2 portion of the study. Randomized means selected by chance, like flipping a coin and double-blind means that neither you nor the investigators will know which dose is assigned. The Phase 2 portion of the study is designed to compare the overall response rate between 2 study arms: azacitidine plus vadastuximab talirine versus azacitidine plus placebo.
This study is closed
Joseph Jurcic, MD
Do You Qualify?
Have you been diagnosed with MDS? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Joseph Jurcic